Benitec Biopharma redomiciled to U.S.

Client(s) Benitec Biopharma Inc. and Benitec Biopharma Limited

Jones Day advised Benitec Biopharma Limited (ASX and NASDAQ listed) ("Benitec Australia") in its redomiciliation from Australia to the U.S. pursuant to a statutory scheme of arrangement under Australian law (the "Scheme"). Upon the completion of the Scheme, all of Benitec Australia's outstanding ordinary shares were exchanged for newly issued shares of common stock of Benitec Biopharma Inc., a Delaware corporation newly incorporated for the Scheme ("Benitec Delaware"); Benitec Australia and its subsidiaries became wholly owned subsidiaries of Benitec Delaware; and Benitec Delaware became the successor of Benitec Australia and its common stock commenced trading on Nasdaq under the symbol "BNTC".

Throughout the redomiciliation process, Jones Day advised Benitec Australia and Benitec Delaware on matters related to the Scheme, corporate governance, listing application, disclosure requirements, tax, and employee benefit-related matters from both U.S. and Australian perspectives.